Pharma BD Deal Intelligence

Charles River Laboratories International, Inc. / Frontage Holdings Corporation

2026 · Asset Purchase · $545M · Pending

Charles River Laboratories entered definitive agreements to acquire Frontage Holdings Corporation's bioanalysis and DMPK operations in Exton, Pennsylvania for approximately $470 million in cash, subject to customary closing adjustments, plus up to an additional $75 million contingent on performance. The acquired business comprises two laboratory facilities totaling roughly 150,000 square feet and about 340 employees providing bioanalysis, biomarker testing and DMPK services for small molecules, biologics and complex therapies, primarily supporting clinical-stage development programs. The operations are expected to contribute approximately $103 million of revenue to Charles River, representing nearly 40% of Frontage's projected 2025 revenue of $256.7 million. The transaction is part of a proposed Frontage breakup in which Charles River takes the Exton operations, Tigermed takes the China business and Acme Bioscience operations, and chairman Song Li retains the remaining non-China operations. Closing is expected in the first half of 2027, subject to regulatory approvals.

This deal is too recent to grade. Critic Score and Outcome Score are assigned after the announcement-week coverage settles and, for Outcome, after the 5-year post-close assessment window opens — expected 2031 at the earliest for this deal, once/if it closes.

Key facts

Related deals

See the full interactive analysis, sources & comparables →